meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced mGC or mGEJC
mGC or mGEJC - 1st line (L1)
mGC or mGEJC - L1 - all population
mGC or mGEJC - L1 - HER2 neg/PDL1 positive
2
mGC or mGEJC - L1 - HER2 negative
1
mGC or mGEJC - L1 - HER2 positive
mGC or mGEJC - L1 - PDL1 positive
4
mGC or mGEJC - 2nd Line (L2)
mGC or mGEJC - L2 - all population
4
mGC or mGEJC - L2 - PDL1 positive
1
mGC or mGEJC - maintenance (M)
mGC or mGEJC - M - HER2 negative
1
mGC or mGEJC - M - HER2 neg/PDL1 positive
1
gene alteration defined cancer
<span style="margin-left: 0em;">chemotherapy</span>
<span style="margin-left: 1em;">Standard of Care (SoC) <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
<span style="margin-left: 0em;">immune chekpoint inhibitors</span>
<span style="margin-left: 1em;">anti-PD-(L)1</span>
<span style="margin-left: 2em;">nivolumab based treatment</span>
<span style="margin-left: 3em;">nivolumab plus SoC <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
Select endpoint...
deaths (OS) (1)
progression or deaths (PFS) (1)
objective responses (ORR) (1)
DOR (1)
TRAE (any grade) (1)
TRAE leading to discontinuation (grade 3-4) (1)
TRAE (grade 3-4) (1)
TRAE leading to death (grade 5) (1)
TRAE leading to discontinuation (any grade) (1)
STRAE (any grade) (1)
STRAE (grade 3-4) (1)
Diarrhoea TRAE (grade 3-4) (1)
Increased ALT TRAE (grade 3-4) (1)
Increase AST TRAE (grade 3-4) (1)
Fatigue TRAE (grade 3-4) (1)
Nausea TRAE (grade 3-4) (1)
Anaemia TRAE (grade 3-4) (1)
Decreased appetite TRAE (grade 3-4) (1)
Asthenia TRAE (grade 3-4) (1)
Thrombocytopenia TRAE (grade 3-4) (1)
Neutropenia TRAE (grade 3-4) (1)
Vomiting TRAE (grade 3-4) (1)
Increased lipase level TRAE (grade 3-4) (1)
Skin and subcutaneous tissue disorders TRAE (grade 3-4) (1)
Gastrointestinal disorders TRAE (grade 3-4) (1)
Endocrine disorders TRAE (grade 3-4) (1)
Hepatobiliary disorders TRAE (grade 3-4) (1)
Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) (1)
Renal and urinary disorders TRAE (grade 3-4) (1)
Peripheral neuropathy TRAE (grade 3-4) (1)
Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) (1)
Peripheral sensory neuropathy TRAE (grade 3-4) (1)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
insufficient data
Evidence network for deaths (OS)
1
CheckMate 649, 2021
Standard of Care (SoC)
nivolumab plus SoC
direct evidence
network meta-analysis
comet plot
result box
odds ratio
A
B
0.5
1.5
1.0
odds ratio for A vs. B
and half 95% CI
T
vs.
C
Standard of Care (SoC)
nivolumab plus SoC
Standard of Care (SoC)
---
NA
nivolumab plus SoC
NA
---
pathologies: 260 - treatments: 863
result logic
×
Study list